Although there are increasing numbers of reported cases of cancer patients with PolE mutations showing good response to immune checkpoint blockade of PD-1 [38,49,50,51,53,54,55,56,57,58], some patients with PolE mutations still do not respond to the treatment. The gene discussed is POLE; the disease is cancer.